User profiles for Neil R. Aggarwal
 | Neil AggarwalAssociate Professor of Medicine, University of Colorado Verified email at cuanschutz.edu Cited by 3569 |
Diverse macrophage populations mediate acute lung inflammation and resolution
NR Aggarwal, LS King… - American Journal of …, 2014 - journals.physiology.org
Acute respiratory distress syndrome (ARDS) is a devastating disease with distinct pathological
stages. Fundamental to ARDS is the acute onset of lung inflammation as a part of the …
stages. Fundamental to ARDS is the acute onset of lung inflammation as a part of the …
[HTML][HTML] CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury
…, K Tsushima, NR Aggarwal… - The Journal of …, 2009 - Am Soc Clin Investig
Acute lung injury (ALI) is characterized by rapid alveolar injury, inflammation, cytokine
induction, and neutrophil accumulation. Although early events in the pathogenesis of ALI have …
induction, and neutrophil accumulation. Although early events in the pathogenesis of ALI have …
Acute lung injury review
K Tsushima, LS King, NR Aggarwal, A De Gorordo… - Internal …, 2009 - jstage.jst.go.jp
The first report of acute respiratory distress syndrome (ARDS) was published in 1967, and
even now acute lung injury (ALI) and ARDS are severe forms of diffuse lung disease that …
even now acute lung injury (ALI) and ARDS are severe forms of diffuse lung disease that …
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA. 4 and BA. 5 in Colorado, USA: a retrospective …
NR Aggarwal, KC Molina, LE Beaty… - The Lancet Infectious …, 2023 - thelancet.com
Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
Advancing precision medicine for acute respiratory distress syndrome
…, LB Ware, HR Wong, NR Aggarwal… - The Lancet …, 2022 - thelancet.com
Acute respiratory distress syndrome (ARDS) is a heterogeneous clinical syndrome. Understanding
of the complex pathways involved in lung injury pathogenesis, resolution, and repair …
of the complex pathways involved in lung injury pathogenesis, resolution, and repair …
Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment
…, Y Eto, MB Drummond, NR Aggarwal… - American journal of …, 2013 - atsjournals.org
Acute lung injury (ALI) causes significant morbidity and mortality. Fibroproliferation in ALI
results in worse outcomes, but the mechanisms governing fibroproliferation remain poorly …
results in worse outcomes, but the mechanisms governing fibroproliferation remain poorly …
Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnoea
…, J Li, MK Shin, C Reinke, NR Aggarwal… - European heart …, 2012 - academic.oup.com
Aims Delayed lipoprotein clearance is associated with atherosclerosis. This study examined
whether chronic intermittent hypoxia (CIH), a hallmark of obstructive sleep apnoea (OSA), …
whether chronic intermittent hypoxia (CIH), a hallmark of obstructive sleep apnoea (OSA), …
[HTML][HTML] Foxp3+ regulatory T cells promote lung epithelial proliferation
JR Mock, BT Garibaldi, NR Aggarwal, J Jenkins… - Mucosal …, 2014 - nature.com
Acute respiratory distress syndrome (ARDS) causes significant morbidity and mortality each
year. There is a paucity of information regarding the mechanisms necessary for ARDS …
year. There is a paucity of information regarding the mechanisms necessary for ARDS …
Real-world evidence of the neutralizing monoclonal antibody sotrovimab for preventing hospitalization and mortality in COVID-19 outpatients
NR Aggarwal, LE Beaty, TD Bennett… - The Journal of …, 2022 - academic.oup.com
Background It is not known whether sotrovimab, a neutralizing monoclonal antibody (mAb)
treatment authorized for early symptomatic coronavirus disease 2019 (COVID-19) patients, is …
treatment authorized for early symptomatic coronavirus disease 2019 (COVID-19) patients, is …
Regulatory T cell DNA methyltransferase inhibition accelerates resolution of lung inflammation
BD Singer, JR Mock, NR Aggarwal… - American journal of …, 2015 - atsjournals.org
Acute respiratory distress syndrome (ARDS) is a common and often fatal inflammatory lung
condition without effective targeted therapies. Regulatory T cells (Tregs) resolve lung …
condition without effective targeted therapies. Regulatory T cells (Tregs) resolve lung …